We are live on ! Find out more
IC

Ikarian Capital Portfolio holdings

AUM $1.23B
1-Year Est. Return 600.17%
This Fund
S&P 500
This Quarter Est. Return
+34.92%
1 Year Est. Return
+600.17%
3 Year Est. Return
+5,763.15%
5 Year Est. Return
+15,527.6%
10 Year Est. Return
–
AUM
$1.07B
AUM Growth
+$237M
Cap. Flow
+$422M
Cap. Flow %
39.55%
Top 10 Hldgs %
35.09%
Holding
191
New
51
Increased
37
Reduced
12
Closed
55

Top Buys

Rank Stock Value
1
ARGX icon
argenx
ARGX
+$32.6M
2
XHB icon
State Street SPDR S&P Homebuilders ETF
XHB
+$16.3M
3
AMLX icon
Amylyx Pharmaceuticals
AMLX
+$13.4M
4
SRPT icon
Sarepta Therapeutics
SRPT
+$12.7M
5
ALPN
Alpine Immune Sciences Inc
ALPN
+$6.77M

Top Sells

Rank Stock Value
1
AKRO
Akero Therapeutics
AKRO
+$10.1M
2
RCKT icon
Rocket Pharmaceuticals
RCKT
+$9.16M
3
SLRN
ACELYRIN
SLRN
+$7.92M
4
PCVX icon
Vaxcyte
PCVX
+$7.26M
5
GPCR icon
Structure Therapeutics
GPCR
+$7.07M

Sector Composition

Rank Sector Weight
1 Healthcare 31.68%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
CMMB
126
Chemomab Therapeutics
CMMB
$11.4M
$109K 0.01%
53,348
– –
SYBX
127
DELISTED
Synlogic
SYBX
$78.7K 0.01%
20,448
– –
STOK icon
128
Stoke Therapeutics
STOK
$1.8B
$63.7K 0.01%
12,116
– –
ANVS icon
129
PUT
Annovis Bio
ANVS
$74.4M
$63.6K 0.01%
+3,400
New +$30.1K
FNCH
130
DELISTED
Finch Therapeutics Group, Inc. Common Stock
FNCH
$24.9K ﹤0.01%
6,892
– –
BCLI
131
DELISTED
BRAINSTORM CELL THERAPUTC
BCLI
$24.6K ﹤0.01%
6,016
– –
ACRS icon
132
Aclaris Therapeutics
ACRS
$726M
$20.5K ﹤0.01%
+19,482
New +$59.4K
VTYX
133
DELISTED
Ventyx Biosciences
VTYX
$14.6K ﹤0.01%
+5,914
New +$56.2K
CLDX icon
134
PUT
Celldex Therapeutics
CLDX
$2.99B
$7.93K ﹤0.01%
200
-771
-79% -$22.7K
ASLN
135
DELISTED
ASLAN Pharmaceuticals Limited American Depositary Shares
ASLN
$6.53K ﹤0.01%
4,428
– –
INSM icon
136
CALL
Insmed
INSM
$21.4B
$6.2K ﹤0.01%
200
+198
+9,900% +$5.13K
ACRS icon
137
CALL
Aclaris Therapeutics
ACRS
$726M
– –
-3,637
Closed -$2.49M
ACRS icon
138
PUT
Aclaris Therapeutics
ACRS
$726M
– –
-5,955
Closed -$4.08M
AKRO
139
CALL
DELISTED
Akero Therapeutics
AKRO
– –
-1,989
Closed -$10.1M
AKRO
140
DELISTED
Akero Therapeutics
AKRO
– –
-200,000
Closed -$10.1M
AKRO
141
PUT
DELISTED
Akero Therapeutics
AKRO
– –
-3,049
Closed -$15.4M
APLS
142
PUT
DELISTED
Apellis Pharmaceuticals
APLS
– –
-412
Closed -$1.57M
BBIO icon
143
CALL
BridgeBio Pharma
BBIO
$15.7B
– –
-3,054
Closed -$8.05M
BHVN icon
144
Biohaven
BHVN
$2.03B
– –
-106,138
Closed -$2.76M
BIVI icon
145
BioVie
BIVI
$11.5M
– –
-4,573
Closed -$1.56M
BMRN icon
146
PUT
BioMarin Pharmaceuticals
BMRN
$11.6B
– –
-1,018
Closed -$9.01M
COGT icon
147
Cogent Biosciences
COGT
$6.65B
– –
-62,766
Closed -$612K
CRNX icon
148
PUT
Crinetics Pharmaceuticals
CRNX
$8.84B
– –
-4,543
Closed -$13.5M
ETNB
149
CALL
DELISTED
89bio
ETNB
– –
-3,504
Closed -$5.41M
KYNB
150
Kyntra Bio
KYNB
$27.2M
– –
-111
Closed -$2.39K
4 5
6
7 8

Similar funds

FLII
First Long Island Investors Jericho, New York $1.23B AUM 14.42% 1-Year Est. Return
NHAS
Novo Holdings A/S Hellerup, Denmark $1.23B AUM 81.32% 1-Year Est. Return
HCA
Harbor Capital Advisors Chicago, Illinois $1.23B AUM 30.56% 1-Year Est. Return
GX
Greylock XIV Menlo Park, California $1.24B AUM
WCM
Windward Capital Management Los Angeles, California $1.23B AUM 23.17% 1-Year Est. Return
MP
Mangrove Partners Greenwich, Connecticut $1.24B AUM 41.74% 1-Year Est. Return
IA
Inspire Advisors Meridian, Idaho $1.23B AUM 18.62% 1-Year Est. Return
IB
Intrust Bank Wichita, Kansas $1.23B AUM 26.34% 1-Year Est. Return

Ikarian Capital's Q4 2023 Portfolio in Review

As of Q4 2023, Ikarian Capital held 191 positions worth $1.07B, up 28% from $831M the previous quarter. Its ten largest holdings account for 35% of the portfolio.

Ikarian Capital deployed $422M of net new capital in Q4 2023, opening 51 new positions and adding to 37 existing holdings. Its largest new stake was argenx: 70,000 shares worth $26.5M.

By sector, the portfolio is most concentrated in Healthcare at 32% of assets, up from 32% a quarter earlier.

On the sell side, the largest reduction was Rocket Pharmaceuticals, an estimated $9.16M trimmed.

  • Ikarian Capital's largest Q4 2023 buy was argenx: 70,000 shares worth $26.5M.
  • Ikarian Capital added most to Disc Medicine in Q4 2023, an estimated $2.67M increase.
  • Ikarian Capital's biggest Q4 2023 reduction was Rocket Pharmaceuticals, cutting an estimated $9.16M.
  • Ikarian Capital fully exited Akero Therapeutics in Q4 2023, selling an estimated $10.1M.
  • Ikarian Capital's ten largest holdings make up 35% of its $1.07B portfolio in Q4 2023.
  • Ikarian Capital opened 51 new positions and closed 55 in Q4 2023.
  • Ikarian Capital's portfolio value rose 28% quarter-over-quarter to $1.07B.

Based on Ikarian Capital's 13F filing for Q4 2023, filed 14 Feb 2024.